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Abstract 
The United States Food and Drug Administration (FDA) has several regulatory programs and 
pathways to expedite the development and approval of therapeutic agents aimed at treating 
serious or life-debilitating conditions. A common feature of these programs is the regulatory 
flexibility, which allows for a customized approval approach that enables market authorization 
on the basis of less rigorous evidence, in exchange for requiring postmarket evidence generation. 
An increasing share of drugs approved by the FDA in recent years are associated with expedited 
programs. In this paper, we provide an overview of the evidentiary standards required by FDA’s 
expedited development and approval programs, summarize the findings of the recent academic 
literature demonstrating some of the limitations of these programs, and outline potential 
opportunities to address these limitations. Recent evidence suggests that therapeutic agents in 
the FDA’s expedited programs are approved on the basis of fewer and smaller studies that may 
lack comparator groups and random allocation, and rather than focusing on clinical outcomes 
for study endpoints, rely instead on surrogate markers of disease. Once on the market, agents 
receiving expedited approvals are often quickly incorporated into clinical practice and evidence 
generated in the postmarketing period may not necessarily address the evidentiary limitations at 
the time of market entry. Furthermore, not all pathways require additional postmarketing studies. 
Evidence suggests that drugs in expedited approval programs are associated with a greater 
likelihood that FDA will take a safety action following market entry. There are several 
opportunities to improve the timeliness, information value, and validity of the pre-and 
postapproval studies of drugs receiving expedited approvals. When use of nonrandomized and 
uncontrolled studies cannot be avoided prior to market entry, randomized trials should be 
mandatory in the postapproval period, unless there are strong justifications for not carrying out 
such studies. In the premarket period, validity of the surrogate markers can be improved by 
more rigorously evaluating their correlation with patient-relevant clinical outcomes. 
Opportunities to reduce the duration, complexity, and cost of postmarketing randomized trials 
should not compromise their validity and instead incorporate pragmatic ‘real-world’ design 
elements. Despite recent enthusiasm for widely using real world evidence, adaptive designs, and 
pragmatic trials in the regulatory setting, caution is warranted until large scale empirical 
evaluations demonstrate their validity compared to more traditional trial designs.    
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Introduction 
 
In the United States, the Food and Drug Administration (FDA) is responsible for ensuring that 
new therapeutic agents are safe and effective. FDA’s review of applications for new drugs and 
biologics (hereafter, novel therapeutic agents) is guided by the Federal Food, Drug, and 
Cosmetic Act, which requires that manufacturers submit data from ‘adequate and well-
controlled’ investigations to determine efficacy.1 In particular, FDA guidance suggests that drug 
manufacturers submit at least two trials, often referred to as ‘pivotal trials’, that provide 
independent evidence of efficacy.2 Although the traditional 10-month review process is designed 
to prevent unsafe or ineffective drugs from entering the market, FDA faces continual pressure to 
accelerate the regulatory review and approval of new drugs, in order to promote innovation and 
provide patients with serious life threatening conditions access to new therapeutic agents as 
quickly as possible.  
 
Over the past 30 years, the US Congress and FDA have introduced four programs (Fast Track 
designation, Accelerated Approval pathway, Priority Review designation, and Breakthrough Therapy 
designation) that aim to expedite the approval process for certain agents that address an ‘unmet 
medical needs in the treatment of a serious or life-threatening condition’ (Figure 1).3 Since their 
inception, there has been a significant increase in the number of therapeutic agents qualifying for 
FDA’s expedited development and review programs.4 However, evidence suggests that these 
programs introduce flexible approval standards that can lead to products being approved on the 
basis of fewer or less robust studies,5 and are associated with greater likelihood that the FDA will 
take a safety-related action after the agent has been approved for use.6  
 
Although a recent study provided an overview of common methodological challenges 
encountered in pivotal clinical trials supporting expedited regulatory approvals,7 different 
methodological and regulatory factors influence the validity of studies conducted in the pre- and 
postapproval periods. In this paper, we first provide an overview of the evidentiary standards 
required by FDA’s expedited development and review programs for therapeutic agents and 
summarize the findings of the recent academic literature demonstrating some of the limitations 
of these programs. We then outline potential opportunities to address these limitations both in 
the pre-and-postapproval setting.  
 
Expedited programs: evidentiary standards 
FDA has four programs that are intended to ‘facilitate and expedite’ the development and review 
of therapeutic agents that have a potential advantage over existing treatments or are the first 
available treatment for a serious disease (Box 1).3  While certain programs, such as Priority Review, 
do not formally change evidentiary standards,3 others allow agents to be approved at earlier 
stages or based on less rigorous testing, which can have important implications for patients, 
physicians, payers, and policy makers.4, 5 In addition, FDA’s policy for requiring postmarketing 
studies varies by program.   
 
Box 1. The expedited development and review programs at the US Food and Drug 
Administration 
Fast Track  
In 1988, FDA formalized the Fast Track designation, which now allows therapeutic agents to be 
approved based on a single phase 2 study if the agent is ‘intended, whether alone or in combination 
with one or more other drugs, for the treatment of a serious or life-threatening disease or 
condition, and it demonstrates the potential to address unmet medical needs for such a disease or 
condition.’3 According to FDA, Fast Track designation can be requested by drug sponsors with or 
after an IND, ‘ideally, no later than the pre-BLA or pre-NDA meeting’.3 When an agent receives 
fast track designation, it can still be eligible for Accelerated Approval and Priority Review.3 Between 
1987 and 2014, 144 (19%) of approved therapeutics had a fast track designation.4 
Priority Review 
In 1992, under the Prescription Drug User Fee Act, FDA established a two-tiered system of review 
times. A drug can receive a Priority Review designation if it ‘treats a serious condition and, if 
approved, would provide a significant improvement in safety or effectiveness.’3 Although Priority 
Review does not formally change evidentiary standards, it establishes that that the FDA deadline to 
make a decision is within six months of submission.  During the review process, priority 
designation is made at the time of original NDA, BLA, or efficacy supplement filing.3 However, 
priority review does not guarantee that a novel therapeutic will be approved. Nearly one in five (18 
or 96, 18.8%) novel therapeutics approved by the FDA after multiple review cycles between 2001 
and 2011 had a Priority Review status.8 Since 1992, Priority Review has been the most common 
expedited approval program (331 of 774 [43%] of new drugs).4  
Accelerated Approval 
In 1992, FDA also instituted the Accelerated Approval program, which allows for the expedited (6 
months) approval of novel therapeutics that treat serious or life-threatening diseases.9 Under the 
Accelerated Approval program, marketing approval is granted based on pivotal trials that use 
surrogate markers, which are biomarkers or intermediate endpoints that are ‘reasonably likely’ to 
predict patient-relevant outcomes, such as mortality and morbidity, as primary endpoints.9 
However, once an agent has been approved, drug sponsors are then required to conduct 
postmarketing trials to describe and verify clinical benefit. Generally, drug sponsors are expected to 
discuss potential accelerated review agents with the FDA review division during development.3 
Approximately 10% of the new drugs approved by the FDA since 1992 have been evaluated 
through the Accelerated Approval program.4, 5 
Breakthrough Therapy 
In 2012, FDA introduced the Breakthrough Therapy designation, which allows drugs that treat serious 
diseases to be approved based on preliminary clinical evidence suggesting substantial improvement 
over available therapies on clinically significant endpoints.3 However, breakthrough drugs must 
eventually be approved or rejected under normal FDA approval standards.3 Breakthrough requests 
are submitted with or after IND, ‘ideally, no later than the end-of-phase 2 meeting’.3  Fast Track 
and Breakthrough Therapy designation drugs are generally approved within 60 calendar days of 
receipt of request.3 To date, there has been limited evaluation of agents receiving Breakthrough 
Therapy designation. 
BLA = Biologic License Application; FDA = Food and Drug Administration; IND = 
Investigational New Drug Application; NDA = New Drug Application 
 
Issues and potential solutions in the premarketing period 
Studies have shown that recent regulatory flexibility has resulted in approvals based on single, 
nonrandomized, or uncontrolled pivotal trials without patient-relevant outcomes or adequate 
participation of the elderly and racial or ethnic minorities.5, 10 Considering that postapproval 
studies of the same therapeutic agents for the same indications are not always carried out,11-13 
trials that support the approval of an agent may be the only source of available evidence. The 
perceptions of the potential treatment benefits of new agents may therefore rely on the results 
from pivotal trials that are used to inform approval. However, the use of a single trial or multiple 
less rigorous trials to inform marketing decisions involves certain trade-offs, particularly risking 
making erroneous inferences about the long term clinical effect of a new treatment. 
 
Single pivotal trials 
Instead of the regular requirement of at least two ‘adequate and well-controlled’ investigations to 
determine efficacy,1 novel therapeutic agents receiving fast track approvals can be approved 
based on a single phase 2 trial.3 Similarly, most accelerated approvals are supported by a single 
study at the time of market entry.5 The findings from an individual, potentially spurious, study 
may provide inaccurate information about the safety and efficacy of a therapeutic agent. 
According to a large empirical evaluation, initially observed effect estimates typically become 
smaller as additional trials are performed.14 Furthermore, findings from single studies may be less 
reliable if their sample sizes are small: previous assessments have shown that small trials are 
associated with substantially exaggerated treatment effects.15, 16 For instance, trials with sample 
sizes ranging from less than 50 to 999 were found to have statistically significantly larger 
treatment effect estimates than trials of 1000 patients or more.16 While some of these findings 
could be explained by the fact that small trials with non-statistically significant findings may be 
more likely to go unpublished than larger trials with non-statistically significant findings and that 
small studies need larger effect sizes to be statistically significant, these concerns may still apply 
to the drug approval process. For instance, it is possible that drug sponsors only submit 
individual trials with the largest treatment effects to the FDA.  
 
Currently, drug sponsors are not required to conduct postmarketing trials to describe and verify 
the clinical benefit of their products receiving Fast Track approval. However, such trials are 
essential to ensure that the treatment effect observed in single pivotal trials are confirmed in 
adequately powered evaluations. According to a recent review of randomized trials published 
after market entry for all novel therapeutic agents approved for 123 indications by the FDA 
between 2005 and 2012 on the basis of limited evidence, only 6 of 33 (18.2%) indications 
approved on the basis of a single trial had at least one randomized, controlled, double-blind 
study using a clinical outcome for the primary endpoint that showed superior efficacy.17  
 
Although postmarketing studies are required in the Accelerated Approval pathway, they are often 
delayed or terminated.13 Even when postapproval trials are completed, they often have similar 
design deficits as pivotal studies.13, 17, 18  In particular, postapproval studies for Accelerated Approval 
drugs are commonly nonrandomized and instead of evaluating accelerated approval agents 
versus comparators, postapproval studies generally include them as background therapies.18 This 
may suggest that agents receiving accelerated approval quickly become part of standard 
treatment, despite the fact that they often lack robust pre-and-postapproval evidence.18  
 
Randomized controlled trials 
Evidence suggests that pivotal trials of therapeutic agents approved through the Accelerated 
Approval pathway are less likely to be randomized.5 Rigorous randomized controlled trials are 
often considered the gold-standard when it comes to evaluating the efficacy of a new drug.19 The 
process of randomly assigning subjects to different intervention groups helps ensure that the 
findings are a result of the intervention instead of systematic differences that may exist between 
groups. There are numerous concerns about the validity of treatment effect estimates from 
nonrandomized study designs. Empirical studies have shown repeatedly that the estimated 
treatment effects from nonrandomized studies tend to be larger compared to those from 
randomized controlled trials.20-22 However, randomization may be inappropriate if the 
intervention is designed to prevent certain rare events or if they target a serious condition 
without any licensed treatments and well-estimated outcomes.23 Furthermore, patients and 
clinicians may also refuse to participate in randomized controlled trials of already-approved 
agents.  
 
Between 2005 and 2012, over half of the pivotal trials for novel therapeutics approved through 
the Accelerated Approval pathway were single-arm trials.5 A comparator group (e.g., active or 
placebo) is often considered an essential part of the scientific method, used to determine 
whether the observed results are actually attributable to the safety and efficacy of a treatment. 
When novel therapeutics are compared to a control arm, it is easier to determine whether the 
drugs are behaving as one would expect from previous knowledge and experience. However, 
when evaluating a new drug, one of the primary goals is to demonstrate a clinical benefit while 
limiting the number of patients who may be exposed to a treatment without clear evidence of 
effectiveness. While randomized controlled trials provide the most reliable information about the 
effect of a treatment, it may not always be possible to allocate patients to multiple groups. For 
instance, when drugs that target extremely rare indications or unmet medical needs are being 
evaluated, there may not be any existing comparator options. However, when only one treatment 
is being evaluated in a trial, it can be difficult to determine whether outcomes or adverse events 
are due to the treatment, disease, or a specific patient characteristics.  
 
In order to rely on the evidence from nonrandomized and/or single-arm trials, it will be 
necessary to establish a framework to specify the circumstances under which these study designs 
can be accepted for the approval of novel therapeutics (Table 1). If single-arm studies are 
utilized, manufacturers should consider multiple sources of historical control data and ensure 
that the patients enrolled in single-arm studies are comparable to patients in historical studies. 
Furthermore, FDA, researchers, clinicians, and research consumers should be cautious when 
interpreting the findings from single-arm studies. When the results from single-arm studies are 
used to guide the approval of novel therapeutics, it should be clearly communicated that 
nonrandomized and uncontrolled study designs do not always allow for causal interpretations.24 
Instead, nonrandomized trials can be used to complement the interpretation of randomized 
trials. Although it may not always be feasible to enroll an adequate number of patients for all 
randomized trials of agents targeting rare conditions within a reasonable period of time,25 
approximately one in three clinical trials supporting rare cancer drug approvals between 
December 1987 and May 2011 were randomized.26  This could suggest that randomized 
controlled trials are a realistic design for evaluating the efficacy and safety of drugs for rare 
indications.26-29 Various frameworks for designing randomized trials in settings where large-scale 
clinical trials may not be typically feasible have been proposed.27, 29 While there may be proper 
justification for nonrandomized trials in exceptional circumstances, manufacturers may need to 
perform randomized trials in other stages of the disease or in different disease settings. For 
instance, when drugs receive accelerated approval, postapproval trials could be conducted in less 
advanced stages of the disease than the initial approval.30  
 
Surrogate markers 
FDA licenses certain therapeutics based solely on the evidence of their effects on surrogate 
markers, which include laboratory measurements, physical signs, or intermediate outcomes.31 
Between 2005 and 2015, 95% of the pivotal trials for novel therapeutics approved under the 
Accelerated Approval pathway had a surrogate marker as the primary trial endpoint.5 
 
Unlike patient-relevant outcomes, which reflect how patients feel or function or how long they 
survive, surrogate markers can accumulate more quickly which can help shorten the duration, 
size, and total cost of pivotal efficacy trials.31-33 While many patient-relevant outcomes are 
discrete, surrogate markers are often continuous and repeatedly measured. This can provide trials 
with more statistical power to detect potential treatment effects.34 These are desirable 
characteristics for sponsors and patients seeking new treatments, as well as for regulators who 
face pressure to shorten testing and review times. There are also important ethical reasons that 
may justify the use of a surrogate marker. For new treatments targeting serious conditions with 
alternative therapies, it may not be feasible to perform long-term studies with patient-relevant 
end points.  
 
While there are successful examples of approved drugs based on established surrogate markers 
(i.e., HIV RNA for AIDS drugs), the role of surrogate markers in guiding patient care and health 
policy remains uncertain and concerning.35-39 The Accelerated Approval pathway distinguishes 
between established surrogate markers and those that are only ‘reasonably likely’ to predict 
clinical benefit.3 Therapeutic agents granted accelerated approval can therefore receive marketing 
authorization on the basis of less established surrogates.  
 
Indeed, surrogate markers do not always provide the same clinical answers as final patient-
relevant outcomes.38 A surrogate marker may not be valid if the treatment effect on the surrogate 
does not correspond to the treatment effect on the final outcome, if there is no consistent 
association between the surrogate and final outcome across multiple studies, and if there is no 
biological plausibility of relation between the surrogate and final outcome.31 Furthermore, 
surrogate markers generally overestimate the treatment effect of interventions.38, 40 Recently, a 
meta-epidemiological study of trials from high impact medical journals found that surrogate 
primary outcomes are more likely to have larger treatment effects than trials reporting final 
patient-relevant primary outcomes.38  
 
There are also concerns related to the validation of surrogate markers. In oncology, most trial-
level validation studies of surrogate markers use only a subset of all available trials and report low 
correlations with survival.41 Such methodological issues may pose significant challenges for 
regulators. For example, in 2008, bevacizumab (Avastin; Roche/Genentech) gained accelerated 
approval for metastatic breast cancer based on pivotal trial evidence suggesting that it could 
improve progression free survival.42 However, the metastatic breast cancer indication of this drug 
was later withdrawn after multiple randomized trials found that bevacizumab did not improve 
overall survival.43  
 
Numerous steps should be considered before promoting the broader use of surrogate markers. 
In the United States, there is a need for an independent evaluation and validation of currently 
used and candidate surrogate markers (Table 1). At a minimum, FDA may need to enhance their 
enforcement of formal empirical verification of surrogate markers. This can help establish the 
performance of a surrogate marker and inform whether certain surrogate markers should 
continue to be used as a substitute of treatment benefit. An FDA advisory committee may be 
necessary to examine why the same surrogate markers for the same drugs do not always replicate 
exactly in postapproval studies.  
 
Recently, Ciani and colleagues outlined a three-step framework that can be used to validate and 
use surrogate-based evidence for health care decision making.31 The first step in the process is to 
establish the level of evidence (e.g., level 1 (highest): randomized controlled trial evidence; level 
2: epidemiological/observational study evidence; level 3: biological plausibility of relation 
between surrogate and patient relevant outcome). The second step is to assess the strength of 
association between the surrogate and final outcome. Although numerous approaches exist, the 
most reliable method is to perform a meta-analysis using patient-level data from all randomized 
controlled trials. The final step involves ‘predicting and quantifying the relation between the 
surrogate and the final outcome, and between the observed effect on the surrogate and the 
expected effect on the final outcome.’ 31 Without a systematic effort to consider, evaluate, and 
report on the predictive value of commonly used surrogate measures, their incorporation in 
regulatory decisions will continue to spark controversy.  
 
Patient heterogeneity 
In order for evidence from pivotal trials to inform decisions in clinical practice, it is essential that 
the patients participating in these trials reflect the population of patients that are expected to 
ultimately use the novel therapeutic agent.10 Since 1998, FDA has taken measures aimed at 
improving and ensuring the representativeness of patients participating in clinical trials. With the 
‘demographic rule’, FDA required drug makers to report the age, sex, and race of clinical trial 
participants in their annual reports to the agency.44 In 2013, FDA released a report describing the 
demographic characteristics of participants in trials of drugs and devices approved in 2011.45 In 
2015, FDA published an investigation on the representativeness of clinical trials supporting 
drugs approved between 2010 and 2012.46 In the same year, FDA piloted the “Drug Trials 
Snapshot” website, which provides data about participants included in trials that supported the 
FDA approval of new therapeutic agents (e.g., potential subgroup differences across sex, race, 
and age groups).47 However, a recent independent evaluation of the demographic characteristics 
of patients participating in pivotal trials for all novel therapeutics approved by the FDA between 
2011 and 2013 found that black and Hispanic patients were underrepresented.10 Overall, white 
patients accounted for almost 80% of pivotal trial participants and the proportion of black and 
Hispanic patients was far less than their representation in the general population.10  
 
Although previous analyses have not explored differences by approval pathway, trial population 
heterogeneity is important to consider as trials continue to become smaller. For example, pivotal 
trials for products approved through the Accelerated Approval pathway have statistically 
significantly smaller sample sizes than non-accelerated approval drugs.5 With smaller pivotal 
trials, the ability to understand potential differences across demographic subgroups will become 
more difficult. 
 
While women and older populations, historically underrepresented in clinical research, appear to 
be better represented in pivotal drug trials over the last 20 years, even greater research 
participation from minority populations will require a concerted effort by both public and 
private stakeholders, taking into account the barriers and facilitators of participation.48  
 
Issues and potential solutions in the postmarketing period 
The approval of novel therapeutics based on less robust evidence highlights the need for 
required postmarketing trials and rigorous surveillance to monitor drug efficacy and safety after 
market introduction. 
 
Postmarketing Requirements  
In 2006, the Institute of Medicine Report on the Future of Drug Safety recommended that the 
FDA adopt a ‘lifecycle’ evaluation approach.49, 50  Under a lifecycle evaluation approach, certain 
agents can be approved based on potentially less robust clinical evidence with the assumption 
that their safety and efficacy will be continuously evaluated after approval.17 Prior to 2007, FDA 
generally could only request that manufacturers voluntarily ‘commit’ to performing 
postmarketing studies or trials (i.e., ‘postmarketing commitments’).51 However, since the Food 
and Drug Administration Amendments Act (FDAAA) in 2007, FDA has had the authority to 
require manufacturers to complete certain postmarketing studies and trials after therapeutics 
receive approval (i.e., postmarketing requirements).51 There are currently four separate authorities 
under which FDA can require drug manufacturers to perform postmarketing studies or clinical 
trial (Box 2).  
Box 2. Food and Drug Administration Postmarking Requirement Authorities 
Accelerated Approval postmarketing requirements: FDA can require postmarketing studies or 
clinical trials to verify efficacy for accelerated approval drugs approved on the basis of surrogate or 
intermediate endpoints ‘reasonably likely’ to predict clinical benefit.3 
Pediatric Research Equity Act (PREA) postmarketing requirements: FDA can approve 
therapeutics if they have been tested in adults; however, certain postmarket pediatric studies, 
evaluating the same drug for the same indication for which they are approved in adults, may be 
deferred.50 
Animal Efficacy Rule postmarketing requirements: In situations where it is unethical to 
conduct trials using human subjects, therapeutics can be approved exclusively based on animal 
studies, but postmarketing studies in humans may still be required.50 
Food and Drug Administration Amendments Act (FDAAA) postmarketing requirements: 
FDA has the authority to require studies that assess known serious risks, signs of serious risks, or 
unexpected serious risks related to the use of a drug .52, 53 
 
While postmarketing requirements can provide important new evidence on the safety and 
efficacy of approved drugs, there have been growing concerns about the fulfillment and 
monitoring of required postmarketing studies.11, 12, 18 An analysis of both postmarketing 
commitments and postmarketing requirements from 2007 to 2011 found that 40% of the 
required studies had not started in 2011.11 In a more recently study of 614 postapproval 
requirements and commitments imposed in 2009 and 2010, approximately 20% of postapproval 
studies had not been started after 5 to 6 years.12 According to an evaluation of 24 indications for 
22 drugs granted ‘conditional’ accelerated approval by the FDA between 2009 and 2013, only 
42% had efficacy confirmed in postapproval trials within 3 years of approval.13  
 
Findings from required studies are an important source of postapproval clinical information and 
can lead to regulatory actions, which can help guide payers, physicians, and patients. For 
approximately half of the postmarketing requirements fulfilled in fiscal year 2014, ‘FDA required 
sponsors to make labeling changes and/or take other actions to ensure the safety of their 
drugs’.53  
 
Postmarket safety actions 
With evidence that the majority of drugs qualify for expedited pathways and that pivotal trials are 
often small, short, and evaluate surrogate markers,4, 5 it is possible that expedited development or 
review can lead to increased risk from safety issues in the postmarketing period. According to a 
recent evaluation, one third of the 222 novel therapeutics approved between 2001 through 2010 
required that the FDA take a postmarket safety action, with accelerated approval therapeutics 
having significantly higher rates.6 In a separate study, drugs approved through expedited 
development and regulatory review pathways between 1997 and 2016 were associated with 
increased safety related label changes after approval.54 In particular, expedited pathway drugs had 
a 40% higher rate of changes to boxed warnings and contraindications compared with 
nonexpedited pathway drugs.54 In a study of new small molecule drugs submitted, approved, and 
launched between 1997 and 2009, drugs approved with a Priority Review were 3.51 times more 
likely to receive a post-marketing boxed warning.55  
 
Moving forward, requirements for postapproval trials should be enhanced (Table 1). 
Investigators should conduct postapproval trials that have adequate sample sizes, follow-up 
durations, and design characteristics. Furthermore, FDA should continue to ensure that 
sponsors complete postmarketing requirements in order to provide additional information about 
the safety, efficacy, and optimal use of a new drug.56 Useful measures to assist in study accrual 
and completion in the postmarket setting include the addition of study sites or plans to conduct 
the confirmatory study in countries where the drug may not yet be commercially available. 
Moreover, measures that would ensure timely completion of the confirmatory studies after 
accelerated approval is granted should be part of the development plan.  
 
Although the FDA’s Sentinel Initiative, which combines administrative claims and clinical data, 
allows for the detection of postmarket safety events using multiple data sources, additional 
collaboration between FDA and other stakeholders will be necessary to ‘develop and maintain an 
effective system for detecting postmarket safety events’.6 This is particularly critical for 
accelerated approval drugs, which have been associated with a greater likelihood that FDA will 
take a safety action in the postmarketing period.  
 
Future outlook 
Recent proposals for FDA reform, including the 21st Century Cures Act, have called for the use 
of nontraditional study designs and evidence from real world non-clinical trial data sources (i.e., 
real world evidence [RWE]) to further speed up the drug approval process.57, 58 Recently, Dr. 
Scott Gottlieb, the FDA commissioner, made remarks to the National Academy of Sciences 
outlining that ‘advancing the adoption of RWE in support of its programs remains a top 
priority.’59 Dr. Gottlieb further outlined that RWE may be ‘especially relevant in settings like rare 
disease or other unmet medical needs, where it can be hard to enroll patients in clinical trials.’59 
Moving forward, it will be important to monitor how the FDA will be using RWE in drug 
approval. So far, FDA’s definition of RWE has been aligned with the use of pragmatic trials in 
actual clinical practice.60 
 
Pragmatic clinical trial designs 
Pragmatic clinical trials are ‘designed for the primary purpose of informing decision-making 
regarding the comparative balance of benefits, burdens and risks of a biomedical or behavioral 
health intervention at the individual or population level.’61  The key feature differentiating 
traditional ‘exploratory’ or ‘mechanistic’ trials from their more ‘pragmatic’ counterparts is the 
degree to which they reflect real-world settings. Relative to traditional designs, pragmatic clinical 
trials often impose fewer restrictions on participant and investigator selection, and treatment 
delivery and follow-up.62 Accordingly, such designs tend to better reflect care delivered in actual 
clinical practice, generating generalizable – externally valid – findings.63-65  
 
Pragmatic clinical trials can also improve the efficiency of evaluations without sacrificing on their 
validity. These practical designs allow for embedding random allocation of treatments in high-
quality observational studies or integrated data systems such as existing population cohorts, 
disease registries, or electronic health records. For example, an existing observational cohort of 
patients with stable, chronic disease can serve as an efficient infrastructure to conduct multiple 
randomized trials of novel therapeutic agents.66, 67 Existing disease registries, observational 
cohorts, or electronic health records can also facilitate reliable data collection.68 For example, 
objective long-term outcomes can be captured in administrative claims or reliable electronic data 
networks currently under development as part of the National Patient-Centered Clinical 
Research Network, an initiative of the Patient-Centered Outcomes Research Institute (PCORI).69 
Therefore, combining elements of randomized and nonrandomized studies in such hybrid 
designs can allow internally valid evaluation of treatment effects in large numbers of people at 
low cost with long periods of follow up (Box 3). 
 
Box 3. Combining elements of randomized and non-randomized studies 
Randomized trials embedded in observational data collection systems have gained in 
popularity in recent years. For example, the Utrecht cohort for Multiple BREast cancer 
intervention studies and Long-term evaLuAtion (UMBRELLA) was conceived as a 
platform to conduct of multiple randomized controlled trials of interventions among 
cancer survivors.70 In an earlier example, researchers in Sweden conducted the Thrombus 
Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial to 
evaluate whether thrombus aspiration reduces mortality in an already existing 
observational registry, maximizing the number of trial participants while minimizing – 
and even eliminating – some of the most complex, time consuming, and costly elements 
of traditional trial designs such as recruitment, follow-up and data collection.71, 72   
 
Despite recent enthusiasm for more widespread use of pragmatic clinical trials in development 
and regulatory decision making,73 key features of such designs may preclude their use in pivotal 
trials supporting regulatory decisions. Currently, clinical trials conducted on investigational new 
drugs are subject to FDA regulations with limited prospect for relaxing restrictions on 
participant and investigator selection, informed consent practices, and protocol-driven follow-up 
mechanisms.74 However, the suitability of pragmatic clinical trials when fulfilling postmarketing 
commitments and requirements of already-approved products should be carefully investigated. 
As the FDA comes under repeated scrutiny for its oversight and enforcement of postmarketing 
studies,12 pragmatic clinical trials can help with effectively and efficiently addressing questions 
that are unanswered at the time of approval. 
 
Adaptive trials 
Recently, the FDA has started to encourage the use of adaptive or innovated clinical trial 
designs. In 2010, FDA issued guidance that designated an adaptive design clinical study as: 
 “…a study that includes a prospectively planned opportunity for modification of one or more specified 
aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in 
the study. Analyses of the accumulating study data are performed at prospectively planned timepoints 
within the study, can be performed in a fully blinded manner or in an unblinded manner, and can occur 
with or without formal statistical hypothesis testing.”75  
 
Considering the costly and time-consuming nature of drug development, adaptive trials have the 
potential to increase the flexibility and efficiency of the drug development process.  Ideally, the 
modifications and adaptations in adaptive trials should be pre-planned and based on the data 
provided in the study. However, changes to eligibility criteria, study dose, treatment duration, 
diagnostic procedures, randomization, study design, study hypotheses, data monitoring and 
interim analyses, and statistical analysis plans can have a big impact of study validity and integrity.  
 
Adaptive trials may require greater statistical expertise during the design, conduct, and analysis 
than in a traditionally-designed randomized controlled trial. According to a recently survey,76 the 
attitudes towards adaptive trials are inconsistent. Biostatisticians, in particular, are not as 
optimistic about the validity and potential conclusions that can be drawn from adaptive trials.76 
Further empirical investigations are needed before establishing a formal role for the use of 
adaptive trial designs in drug development and approval.  
 
While efforts are underway to ensure the internal validity of findings obtained from adaptive trial 
designs when compared to traditional ‘mechanical’ trial designs, significant opportunities exist to 
lower the cost and complexity of randomized trials without compromising their validity. 
 
Conclusions 
As the number of novel therapeutic agents included in expedited approval pathways and 
programs has increased, there are several opportunities for improving the timeliness and 
information value of clinical trials conducted for regulatory purposes. In recent years, an 
increasing number of agents have entered the United States market on the basis of a single 
pivotal trial and trials using surrogate markers as primary endpoints or employing non-
randomized or uncontrolled designs. Moving forward, clear regulatory guidance is necessary to 
identify the circumstances in which the use of surrogate markers is warranted. Efforts are needed 
to evaluate and reach consensus on the predictive validity of current and future surrogate 
markers. In cases where agents are approved on the basis of single-arm trials, randomized 
controlled trials should be required in the postmarketing period, unless there are strong 
justifications, from an ethical or feasibility perspective, for not carrying out such studies. In 
parallel, introducing elements of pragmatic (real-world) designs into randomized trials, especially 
in the postmarketing setting, can help with reducing the complexity, and hence cost, of such 
studies, which play a pivotal role in evaluating the effectiveness of newly marketed agents in the 
real world. Although RWE, adaptive designs, and pragmatic trials hold great promise, caution is 
warranted until empirical studies demonstrate the validity of such designs as compared to 
traditional, protocol-driven randomized controlled trials.  
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 Table 1. Recommendations to improve the design and analyses of clinical trials 
Area Investigators and regulators should: 
Single-arm trials Identify the circumstances where the use of single-arm trials may be warranted  
 When use is justified, consider multiple sources of historical control data 
 Ensure the comparability between patients in single-arm studies and potential 
historical controls 
 Provide cautious (non-causal) interpretations of the findings from single-arm 
studies 
 Ensure postmarketing evidence generation requirements include randomized 
controlled trials 
Trial outcomes Rely on surrogate markers that have been validated or validate surrogate 
markers using a three-step process31 
 Enhance the process to evaluate and report on the validity of currently used 
and candidate surrogate markers 
 Ensure that patients and physicians understand how to interpret the results 
from trials with surrogate markers 
 Require postmarketing trials that incorporate patient-relevant, clinical 
outcomes 
Accrual and 
complexity 
Consider the addition of study sites or plans to conduct confirmatory studies 
in countries where certain agents may not yet be commercially available 
 Introduce elements of pragmatic (‘real-world’) designs and use routinely 
available data sources to reduce the complexity of postmarketing randomized 
trials 
Adaptive trials Ensure that modifications and adaptations are pre-planned and based on the 
data provided in the study 
 Interpret findings obtained from adaptive trials with caution until empirical 
evaluations confirm their validity 
 
 
 
 Figure 1. Expedited development and review programs and their evidentiary standards  
 
 
 
 
 
 
 
 
 
 
 
 
  
Fast Track designation (1988)
- Drugs that treat serious or life-threatening diseases 
or conditions
- Evidentiary requirements: drugs can be approved 
based on a single phase 2 study
- Approved within 60 calendar days of  receipt of  
request
- 144 of  774 (19%) of  approved drugs between 
1987-20144
Accelerated Approval pathway (1992)
- Drugs that treat serious or life-threatening diseases or 
conditions
- Evidentiary requirements: drugs can be approved on the basis 
of  surrogate endpoints that are ‘reasonably likely’ to predict 
patient relevant outcomes 
- 6 month review
- 68 of  774 (9%) of  approved drugs between 1987-20144
Priority Review designation (1992)
- Drugs appear to offer therapeutic advantage over 
available therapy
- Evidentiary requirements: no change
- 6 month review
- 331 of  774 (43%) of  approved drugs between 1987-
20144
Breakthrough Therapy designation (2012)
- Drugs that treat serious diseases for which preliminary clinical 
trial evidence suggests substantial improvement over existing 
therapies on one or more clinically important endpoints
- Evidentiary requirements: no change
- Approved within 60 calendar days of  receipt of  request
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